Delving into the Latest Updates on Anti-CD79B CAR-T (Wuhan Bio-Raid ) with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms-

Target

CD79B

Action

inhibitors

Mechanism

CD79B inhibitors(B-cell antigen receptor complex-associated protein beta chain inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Hematologic Neoplasms

Inactive Indication-

Originator Organization

Wuhan Bio-Raid Biotechnology Co., Ltd.

Active Organization

Wuhan Bio-Raid Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

BACKGROUNDAlthough chimeric antigen receptor (CAR) T-cell therapy targeting antigens expressed in refractory and relapsed non-Hodgkin B-cell lymphoma, such as CD19 and CD22, has achieved encouraging clinical effects, some patients fail to attain remission, or relapse after CAR T-cell therapy, which has been ascribed to the loss of the target antigens.OBJECTIVETo evaluate CD79b as an alternative target for CAR T-cell B-cell lymphoma therapy.PATIENT AND METHODSThe expression of CD79b in different B-cell lymphomas was determined. Anti-CD79b CAR T-cells expressing one of two different CARs were generated, and a series of in vitro and in vivo experiments were conducted to assess the CAR T-cell function.RESULTSWe found that CD79b was extensively expressed on the tumor cells of patients with various types of lymphoma regardless of stage, subtype, and cytogenetic and molecular features. Anti-CD79b CAR T-cells were highly specific and effective for the treatment of B-cell lymphomas.CONCLUSIONSOur data indicate that CD79b could be used as a target for CAR T-cell therapy of B-cell lymphomas, and further clinical development is warranted.

100 Deals associated with Anti-CD79B CAR-T (Wuhan Bio-Raid )

Login to view more data